Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 2/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | IDH1 | O75874 | 1/20 | 0.39 |
| ▸ | DAO | P14920 | 3/20 | 0.38 |
| ▸ | AADAT | Q8N5Z0 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | KIF11 | P52732 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20516425 | 1.00 | CES2 (0.42) | CES2PPARGHDAC1HDAC6IDH1 | |
| SCHEMBL20516445 | 0.79 | GAA (0.54) | HDAC1HDAC6GAA | |
| SCHEMBL20516443 | 0.79 | GAA (0.54) | HDAC1HDAC6GAA | |
| SCHEMBL7623748 | 0.73 | CES2 (0.47) | CES2HDAC1HDAC6GAAKIF11 | |
| SCHEMBL20516417 | 0.73 | CES2 (0.44) | CES2HDAC1HDAC6GAA | |
| SCHEMBL20516416 | 0.73 | CES2 (0.44) | CES2HDAC1HDAC6GAA | |
| SCHEMBL7620532 | 0.72 | CES2 (0.43) | CES2HDAC1HDAC6GAAKIF11 | |
| SCHEMBL22901963 | 0.72 | TRPM8 (0.38) | CES2PPARGHDAC1HDAC6 | |
| SCHEMBL3554150 | 0.70 | HDAC6 (0.67) | CES2HDAC1HDAC6GAA | |
| SCHEMBL3554155 | 0.70 | HDAC6 (0.67) | CES2HDAC1HDAC6GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10336709-B2 | Lp-PLA2 inhibitors | ABIDE THERAPEUTICS, INC (US) | 2019-07-02 | — | — | US | disclosed |
| US-20180282288-A1 | LP-PLA2 INHIBITORS | H. LUNDBECK A/S (DK) | 2018-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180282288-A1 | LP-PLA2 INHIBITORS | PLA2G12A, PLA2G12B, PLA2G4B | CES2 1143/4885PPARG 502/4885HDAC1 1289/4885 |
| US-10336709-B2 | Lp-PLA2 inhibitors | PLA2G12A, PLA2G12B, PLA2G1B | CES2 1176/4885PPARG 494/4885HDAC1 1457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.